Hookipa Pharma Inc (NASDAQ:HOOK) – Stock analysts at Svb Leerink issued their Q1 2019 earnings per share (EPS) estimates for Hookipa Pharma in a research note issued to investors on Monday, May 13th. Svb Leerink analyst A. Berens anticipates that the company will post earnings of ($0.55) per share for the quarter. Svb Leerink currently has a “Outperform” rating and a $20.00 price target on the stock. Svb Leerink also issued estimates for Hookipa Pharma’s Q2 2019 earnings at ($0.40) EPS, Q3 2019 earnings at ($0.48) EPS, Q4 2019 earnings at ($0.60) EPS, FY2019 earnings at ($2.01) EPS, FY2020 earnings at ($1.98) EPS, FY2021 earnings at ($3.98) EPS, FY2022 earnings at ($3.15) EPS and FY2023 earnings at ($3.35) EPS.
Several other research analysts have also weighed in on the stock. Leerink Swann assumed coverage on shares of Hookipa Pharma in a research report on Monday, May 13th. They set an “outperform” rating and a $20.00 target price on the stock. Bank of America assumed coverage on shares of Hookipa Pharma in a research report on Monday, May 13th. They set a “buy” rating and a $17.00 target price on the stock. Finally, Royal Bank of Canada assumed coverage on shares of Hookipa Pharma in a research report on Monday, May 13th. They set an “outperform” rating and a $23.00 target price on the stock.
In other Hookipa Pharma news, major shareholder Sofinnova Capital Vi Fcpr purchased 357,142 shares of Hookipa Pharma stock in a transaction on Tuesday, April 23rd. The shares were bought at an average price of $14.00 per share, with a total value of $4,999,988.00. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Also, insider Bros. Advisors Lp Baker purchased 892,857 shares of Hookipa Pharma stock in a transaction on Tuesday, April 23rd. The stock was acquired at an average cost of $14.00 per share, for a total transaction of $12,499,998.00. The disclosure for this purchase can be found here.
About Hookipa Pharma
HOOKIPA Pharma Inc, a clinical-stage biopharmaceutical company, develops immunotherapeutics targeting infectious diseases and cancers based on its proprietary arenavirus platform. The company's lead infectious disease product candidate is HB-101, which is in a randomized double-blinded Phase 2 clinical trial in cytomegalovirus-negative patients awaiting kidney transplantation from cytomegalovirus-positive donors.
Further Reading: What is a Tariff?
Receive News & Ratings for Hookipa Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hookipa Pharma and related companies with MarketBeat.com's FREE daily email newsletter.